Previous 10 | Next 10 |
Madrigal Pharmaceuticals (NASDAQ:MDGL) has announced data from a Phase 3 study designed to evaluate its lead asset, resmetirom in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Data from the already concluded 171-patient open-label arm of the...
This final read-out of the 52-week open-label resmetirom 100 mg treatment study of 171 patients with presumed non-alcoholic steatohepatitis (NASH) and fibrosis, identified using non-invasive tests, demonstrate that resmetirom: provided rapid and sustained reduction in liver fat ...
Madrigal Pharmaceuticals (NASDAQ:MDGL): Q3 GAAP EPS of -$3.79 beats by $0.09. Press Release As of September 30, 2021, Madrigal had cash, cash equivalents and marketable securities of $299.1 million, compared to $284.1 million at December 31, 2020. The increase in cash and marketable securitie...
CONSHOHOCKEN, Pa., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides a summary of corporate accomplishments and reports its third quarter 2021 financial results. Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, “Throu...
The race is on to get a commercial biotech treatment asset targeting Nonalcoholic steatohepatitis, or “NASH”. NASH is sadly one of the fastest growing treatable major health problems on the planet right now, and analysts believe the resulting commercial opportunity could be as b...
Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
CONSHOHOCKEN, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announces its support of the Fatty Liver Foundation, the leading patient advocacy organization focuse...
Hepion Pharmaceuticals is a promising candidate in the race for an effective drug for treating NASH. Although still in a very early phase of trials, CRV431 has presented very promising preclinical results. The ALT reduction obtained in last phase IIa trial outperformed all competi...
Madrigal Pharmaceuticals (NASDAQ:MDGL): Q2 GAAP EPS of -$3.72 misses by $0.14. As of June 30, 2021, Madrigal had cash, cash equivalents and marketable securities of $323.8M, compared to $284.1M at December 31, 2020. Press Release For further details see: Madrigal Pharmaceuticals E...
CONSHOHOCKEN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of corporate accomplishments. Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, “The Ma...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...